SusanLGreenspanMD

Endocrinology • Pittsburgh, PA

Diabetes, Lipid Metabolism

Professor of Medicine, University Pittsburgh

Join to view full profile

Dr. Greenspan is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Greenspan's full profile

Already have an account?

Office
3471 5th Ave
Ste 1110
Pittsburgh, PA 15213
Phone+1 412-692-2472

Education & Training

Massachusetts General HospitalFellowship, Endocrinology, Diabetes, and Metabolism, 1982 - 1985
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1980 - 1982
Harvard Medical SchoolClass of 1979

Certifications & Licensure

CA State Medical License 1982 - Present
PA State Medical License 1999 - 2024
MA State Medical License 1981 - 2001
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Endocrinology, Diabetes and Metabolism

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2005-2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011
Pittsburgh Magazine Castle Connolly, 2005-2007, 2010-2011

Clinical Trials

Prevention of Osteoporosis in Men With Prostate Cancer Start of enrollment: 2002 May 01
Completed
Phase 3
The Prevention of Osteoporosis in Premenopausal and Newly Postmenopausal (Up to 8 Years) Women With Breast Cancer Following Chemotherapy (REBBeCA Study) Start of enrollment: 2003 May 01
Completed
Not Applicable
Prevention of Osteoporosis in Men With Prostate Cancer on Androgen Deprivation Therapy (POP Study) Start of enrollment: 2002 May 01
Completed
Phase 3
Zoledronic Acid for Osteoporosis in the Elderly Start of enrollment: 2007 Dec 01
Completed
Not Applicable
Preventing Osteoporosis Using Denosumab Start of enrollment: 2016 Jun 01
Completed
Phase 4
Romosozumab Use to Build Skeletal Integrity Start of enrollment: 2021 Sep 15
Recruiting
Phase 4
Roles: Principal Investigator
Preserving Geriatric Muscle With an Osteoporosis Medication Start of enrollment: 2024 Feb 08
Recruiting
Phase 4
Roles: Contact, Sponsor-Investigator
Join now to see all

Publications & Presentations

PubMed

18 citations
Vertebral Fractures and the Misclassification of Osteoporosis in Men With Prostate Cancer
Sarah M. Sullivan, Julie M. Wagner, Neil M. Resnick, Joel B. Nelson, Subashan Perera
Journal of Clinical Densitometry. 2011-07-01
32 citations
Vertebral fractures and trabecular microstructure in men with prostate cancer on androgen deprivation therapy.
Susan L. Greenspan, Julie M. Wagner, Joel B. Nelson, Subashan Perera, Cynthia A. Britton
Journal of Bone and Mineral Research. 2013-02-01
108 citations
A Randomized Trial of a Multifactorial Strategy to Prevent Serious Fall Injuries
Shalender Bhasin, Thomas M. Gill, David B. Reuben, Nancy K. Latham, David A. Ganz
The New England Journal of Medicine. 2020-07-08

Press Mentions

COVID Interrupts Bone Therapy for Many; Vegan vs Mediterranean DietFebruary 14th, 2021
How Has COVID-19 Affected the Treatment of Osteoporosis? An IOF-NOF-ESCEO Global SurveyFebruary 8th, 2021
Efficacy and Safety of Single-Dose Zoledronic Acid for Osteoporosis in Frail Elderly Women: A Randomized Clinical TrialJuly 22nd, 2020
Join now to see all

Grant Support

Osteoporosis In Older Men And WomenNational Institute Of Diabetes And Digestive And Kidney Diseases2003–2012
Research Career Development CoreNational Institute On Aging2009–2011
Maintenance Of Skeletal Integrity In Frail EldersNational Institute On Aging2007–2011
Research And Development CoreNational Institute On Aging2004–2008
Prevention Osteoporosis Premenopausal/Postmenopausal Women W/Breast CancerNational Center For Research Resources2005
Once Wkly Bisphosphonate Preventing Osteoporosis In Hypogondal MenNational Center For Research Resources2005
F/U PTH Alendronate Combo Trmnt Osteoporosis PATH IINational Center For Research Resources2005
Bone Loss In Men W/Prostate Cancer Treated W/Androgen Deprivation TherapyNational Center For Research Resources2005
Prevention Of Osteoporosis In Men With Prostate CancerNational Institute Of Diabetes And Digestive And Kidney Diseases2002–2005
PTH And Alendronate In The Treatment Of OsteoporosisNational Center For Research Resources2004
Prevention Osteoporosis In Premenopause/PostmenopauseNational Center For Research Resources2004
Lasofoxifene For Women At Risk For OsteoporosisNational Center For Research Resources2004
Bone Loss In Men With Prostate CancerNational Center For Research Resources2004
Bisphosphonate Prevention Of Osteoporosis In MenNational Center For Research Resources2004
Bariatric Surgery Effect On Bone Mass/ Bone MetabolismNational Center For Research Resources2004
Reference Range For The QUS 2 Ultrasonometer For Evaluation Of OsteoporosisNational Center For Research Resources2000–2002
Precision Assessment Of QUS 2 UltrasonometerNational Center For Research Resources2000–2002
Phase III Cyclic Tiludronate--Postmenopausal OsteoporosiNational Center For Research Resources2000–2002
Efficacy Of QUS 2 Ultrasonometer For Diagnosis Of OsteoporosisNational Center For Research Resources2000–2002
Calcaneal Bone Assessment Technologies To Dual X Ray AbsorptiometryNational Center For Research Resources2000–2002
Screening High Risk Population For Clinically Significant Gaucher DISNational Center For Research Resources1999–2002
Alendronate Once Weekly For Osteoporosis PreventionNational Center For Research Resources1999–2002
Alendronate Once &Twice Weekly For Osteoporosis TreatmentNational Center For Research Resources1999–2002
Bisphosphonate-Hormonal Therapy For OsteoporosisNational Center For Research Resources1997–2002
Raloxifene Hydrochloride, Placebo And Premarin In Prevention Of OsteoporosisNational Center For Research Resources1995–2002
Efficacy Of Mk-0677 And Alendronate On Bone Turnover And DensityNational Center For Research Resources1997–2000
Bone Loss Prevention After Acute HIP Fracture In The ElderlyNational Center For Research Resources1997–2000
Alendronate On Bone Density Maintenance In Female Nursing Home PatientsNational Center For Research Resources1997–2000
Effect Of Alendronate, Estrogen And Combination Therapy For OsteoporosisNational Center For Research Resources1995–2000
Femoral Osteoporosis In Elderly WomenNational Institute On Aging1995–1999
Phase III Study Of Intermittent Cyclical TiludronateNational Center For Research Resources1995–1999
Insulinlike Growth Factor I And Bone Marker Status After HIP FractureNational Center For Research Resources1997
Diabetes In A Patient With OsteoporosisNational Center For Research Resources1997
Role Of Bisphosphonate Therapy In Maintenance Of Skeletal IntegrityNational Center For Research Resources1995–1997
Efficacy Of Alendronate On Bone Density Maintenance In Female Nursing Home PTSNational Center For Research Resources1996
Comparison Of Calcaneal Bone Assessment Technologies To Dual X Ray AbsorptiometryNational Center For Research Resources1996
Biochemical Correlates Of Bone LossNational Center For Research Resources1995–1996
HIP Fracture Risk Prediction By Quantitative Digital RadiographyNational Center For Research Resources1995
Finasteride Indices On Bone Mineral Metabolism In Benign Prostate HyperplasiaNational Center For Research Resources1995
Effect Of Pamidronate On Chronic Thyroid Hormone-Induced Bone TurnoverNational Center For Research Resources1995
Diurnal Variation In PTH And Calcium While On Alendronate TherapyNational Center For Research Resources1995